Penumbra Inc. (NYSE:PEN) shares surged 6.29% in after-hours trading on Tuesday, following the release of its impressive fourth-quarter results and optimistic 2025 guidance. The medical device maker reported adjusted earnings of $0.97 per share, comfortably beating analysts' expectations of $0.90 per share. Revenue for the quarter came in at $315.52 million, outperforming the consensus estimate of $311.55 million.

The company's solid performance was driven by robust demand for its products, with revenue increasing by 10.83% compared to the same period last year. Penumbra's management team expressed confidence in the company's growth prospects, guiding for full-year 2025 revenue between $1.34 billion and $1.36 billion, which aligns with analysts' expectations.

Investors reacted positively to Penumbra's strong results and upbeat guidance, sending the stock soaring in after-hours trading. The medical device industry continues to benefit from increasing healthcare spending and technological advancements, positioning Penumbra well for continued growth in the coming year.